XERIS BIOPHARMA HOLDINGS, INC. Sublease Income
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Sublease Income of $272.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for the quarter ending 2026-06-30 was $272.00K, a 6.53% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for the quarter ending 2026-03-31 was $266.00K, a 9.22% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for the quarter ending 2025-12-31 was $301.00K, a 3.44% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for the quarter ending 2025-09-30 was $216.00K, a 11.34% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for fiscal 2025 was $1.10M, a 86.61% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for fiscal 2024 was $590.00K, a 173.15% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for fiscal 2023 was $216.00K, a 1.89% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. sublease income for fiscal 2022 was $212.00K.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $272.00K 10-Q · filed 2026-08-06 | $538.00K 10-Q · filed 2026-08-06 | $839.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $266.00K 10-Q · filed 2026-05-07 | $567.00K derived: sum of 2 quarters · filed 2026-05-07 | $783.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $301.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $517.00K derived: sum of 2 quarters · filed 2026-03-02 | $808.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.10M 10-K · filed 2026-03-02 |
| 2025-09-30 | $216.00K 10-Q · filed 2025-11-06 | $507.00K derived: sum of 2 quarters · filed 2026-08-06 | $800.00K 10-Q · filed 2025-11-06 | $1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $291.00K 10-Q · filed 2026-08-06 | $584.00K 10-Q · filed 2026-08-06 | $875.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $293.00K 10-Q · filed 2026-05-07 | $584.00K derived: sum of 2 quarters · filed 2026-05-07 | $778.00K derived: sum of 3 quarters · filed 2026-05-07 | $830.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $485.00K derived: sum of 2 quarters · filed 2026-03-02 | $537.00K derived: sum of 3 quarters · filed 2026-03-02 | $590.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $194.00K 10-Q · filed 2025-11-06 | $246.00K derived: sum of 2 quarters · filed 2025-11-06 | $299.00K 10-Q · filed 2025-11-06 | $353.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $52.00K 10-Q · filed 2025-08-07 | $105.00K 10-Q · filed 2025-08-07 | $159.00K derived: sum of 3 quarters · filed 2026-03-02 | $213.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $53.00K 10-Q · filed 2025-05-08 | $107.00K derived: sum of 2 quarters · filed 2026-03-02 | $161.00K derived: sum of 3 quarters · filed 2026-03-02 | $215.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $108.00K derived: sum of 2 quarters · filed 2026-03-02 | $162.00K derived: sum of 3 quarters · filed 2026-03-02 | $216.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $54.00K 10-Q · filed 2024-11-08 | $108.00K derived: sum of 2 quarters · filed 2024-11-08 | $162.00K 10-Q · filed 2024-11-08 | $216.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $54.00K 10-Q · filed 2024-08-08 | $108.00K 10-Q · filed 2024-08-08 | $162.00K derived: sum of 3 quarters · filed 2025-03-06 | $216.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $54.00K 10-Q · filed 2024-05-09 | $108.00K derived: sum of 2 quarters · filed 2025-03-06 | $162.00K derived: sum of 3 quarters · filed 2025-03-06 | $214.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $108.00K derived: sum of 2 quarters · filed 2025-03-06 | $160.00K derived: sum of 3 quarters · filed 2025-03-06 | $212.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $54.00K 10-Q · filed 2023-11-09 | $106.00K derived: sum of 2 quarters · filed 2023-11-09 | $158.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $52.00K 10-Q · filed 2023-08-08 | $104.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $52.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |